Amalia-Andrea Titieanu

Amalia-Andrea Titieanu

Auto-generated profile, based on publicly available information

Amalia-Andrea Titieanu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2023 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
ATAmalia-Andrea Titieanu
Amalia-Andrea Titieanu
VCVlad Andrei Cianga
Vlad Andrei Cianga
CDCatalin Doru Danaila
Catalin Doru Danaila
MDMIHAIELA LOREDANA DRAGOȘ
MIHAIELA LOREDANA DRAGOȘ
ICIVANOV IULIU CRISTIAN
IVANOV IULIU CRISTIAN
ADAngela Dascalescu
Angela Dascalescu

24 March 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
DFDiana-Marina Fortoes
Diana-Marina Fortoes
ENElena Nicorici
Elena Nicorici
CMCosmin Minciuna
Cosmin Minciuna
VCVlad Andrei Cianga
Vlad Andrei Cianga
RTRamona Timofte
Ramona Timofte
CDCatalin Danaila
Catalin Danaila
Aim: To assess the real-world efficacy of brentuximab vedotin and PD-1 inhibitors versus historical chemotherapy-only salvage regimens in relapsed/refractory classic Hodgkin lymphoma. Methods: Retrospective single-center study of two cohorts (n=30 each) treated between 1996–2012 (historical) and 2017–2021 (immunotherapy), with survival endpoints (OS, PFS, EFS1-3) analyzed by Kaplan–Meier and log-rank tests. Results: The immunotherapy group achieved a higher overall response rate (80% vs. 36.7%, p=0.001), longer median OS (47 vs. 30 months) and superior EFS1–3 (33 vs. 16 months, 32.5 vs. 8 months, 38 vs. 23 months; all p 0.05) compared to historical controls. Conclusion: Incorporation of brentuximab vedotin and PD-1 blockade before and after autologous SCT significantly improves response and survival outcomes in relapsed/refractory Hodgkin lymphoma, supporting earlier use of these agents in salvage and frontline settings.